BRAF and central nervous system cancer: Adaptive resistance to BRAFi/MEKi is well documented in BRAF V600E mutant cancers.2,5,43,44 To assess whether SHP2i can restore sensitivity in BRAFi-resistant glioma lines, we generated dabrafenib-resistant BRAF V600E altered glioma cell lines through prolonged culture in increasing doses of dabrafenib.